SOPHiA GENETICS
SOPHiA GENETICS operates SOPHiA DDM™, a cloud-native AI SaaS platform that enables hospitals, clinical labs, and biopharma to analyze and interpret genomic, radiomic, and multimodal healthcare data, serving 990+ institutions across 75+ countries with a hybrid recurring subscription and usage-based model.
- Company typePublic
- Founded2011
- HeadquartersBoston, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingSoftware
What SOPHiA GENETICS does
SOPHiA GENETICS SA, founded in 2011 by Dr. Jurgi Camblong and dual-headquartered in Rolle, Switzerland and Boston, Massachusetts, operates a cloud-native, AI-driven SaaS platform called SOPHiA DDM™ that enables hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data while retaining control of patient samples and information. The platform combines proprietary algorithms (PEPPER, MUSKAT, CARDAMOM, GIInger, MUSTARD, MOKA, ABCD, STAR ANISE) with CUMIN® molecular barcoding technology and is tech-agnostic across major sequencing platforms (Illumina, Thermo Fisher, MGI, Element Biosciences, Complete Genomics). Application modules span solid tumors, hereditary cancers, blood cancers, liquid biopsy, rare disorders, and inherited disorders; add-on modules include Alamut™ Visual Plus variant interpretation and the newly launched SOPHiA DDM™ Digital Twins, which creates AI-driven virtual patient simulations for personalized oncology decision-making.
The company monetizes through a hybrid model: recurring platform subscriptions and per-analysis usage fees for the SOPHiA DDM™ cloud, plus higher-margin BioPharma services that include co-development of companion diagnostics (notably via the Myriad Genetics hybrid CDx partnership), clinical trial assay design, real-world data analytics, and biomarker discovery. Pricing is quote-based, with average selling price per patient reportedly rising from $50 in 2015 to $170 currently, and customer base of 537 core genomics customers across 990+ healthcare institutions in 75+ countries. The company also distributes white-labeled MSK-IMPACT® and MSK-ACCESS® assays through its MSK partnership and has expanded U.S. footprint via two large integrated health systems with up to 60,000 patients/year in hereditary cancer and rare disease applications.
SOPHiA GENETICS is publicly traded on Nasdaq (ticker SOPH), with FY2025 revenue of $77.3M (19% YoY), Q1 2026 revenue of $21.7M (22% YoY), 2026 guidance of $92-94M, 75% adjusted gross margin, and a 2026 adjusted EBITDA breakeven target. The company has 251-500 employees across 28 countries (30% with PhDs), holds multiple CE-IVD certifications (IVDR-compliant in EEA, UK, Switzerland, Israel), and is certified to ISO 27001/27017/27018, ISO 13485, SOC 2 Type 2, HIPAA, and GDPR. Recent capital actions include a $57.5M oversubscribed public offering in June 2026, a $50M debt facility from Perceptive Advisors (May 2024, expanded by $25M in early 2026), and a leadership transition effective July 1, 2026 with Ross Muken succeeding Dr. Camblong as CEO.
SOPHiA GENETICS firmographics
Firmographics- Name
- SOPHiA GENETICS
- Legal name
- SOPHiA GENETICS SA
- Website
- https://sophiagenetics.com
- Company type
- Public
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- SOPHiA GENETICS operates SOPHiA DDM™, a cloud-native AI SaaS platform that enables hospitals, clinical labs, and biopharma to analyze and interpret genomic, radiomic, and multimodal healthcare data, serving 990+ institutions across 75+ countries with a hybrid recurring subscription and usage-based model.
- Ownership category
- akta.pro rank
SOPHiA GENETICS industry classification
Industry- Product category
- Clinical Genomics Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Computer Systems Design and Related Services (54151), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)
- akta.pro secondary industries
- Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
Keywords
Where SOPHiA GENETICS is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
SOPHiA GENETICS business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- Platform Subscription / Recurring SaaS: Recurring subscription and per-test fees for use of the SOPHiA DDM™ cloud platform, including 'Dry Lab', 'Bundle' and 'Integrated Access Mode' offerings that combine IVD/RUO NGS applications with the platform; pricing is quote-based and not publicly disclosed.
- Usage-Based Analysis Volume: Revenue scales with the number of genomic analyses processed on the platform; company has reported 35,000 patient cases processed monthly and 391,000 analyses in 2025; average selling price per patient increased from $50 (2015) to $170 currently.
- BioPharma Companion Diagnostic & Trial Services: Revenue from co-development and deployment of companion diagnostics (CDx), clinical trial assays, real-world data analytics, and biomarker discovery with pharma/biotech partners; includes hybrid centralized/decentralized model with partners like Myriad Genetics.
- Alamut™ Visual Plus Licensing: Standalone variant annotation/visualization software offered as an add-on module with a 'Request a Free Trial' CTA; represents licensing of proprietary software IP.
- Professional Services & MaxCare Program: Tailored enablement, LIMS integration, application automation, training, and ongoing support services bundled with platform adoption under the SOPHiA DDM™ MaxCare Program.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise platform access — quote-based |
| Usage-based | Pay-as-you-go | Per-analysis / volume-based pricing |
| Other | Annual | Alamut™ Visual Plus free trial / licensed |
Go-to-market motion5 records
Distribution channels5 records
Marketing channels9 records
SOPHiA GENETICS product offering
Product offeringCore offering
SOPHiA GENETICS builds and operates the SOPHiA DDM™ cloud-native AI platform that ingests raw NGS, radiomic and multimodal data and produces standardized, clinically validated variant interpretations and reports for hospitals, clinical laboratories and biopharma customers across 75+ countries. The platform is delivered as enterprise SaaS (Dry Lab, Bundle, Integrated Access Mode), with proprietary molecular barcoding (CUMIN®) and a suite of calling algorithms enabling CE-IVD genomic applications in oncology and rare disorders, and supports companion diagnostic co-development with pharmaceutical partners.
Differentiator
Problem solved
Functional benefit
Brands
- SOPHiA DDM™: AI-powered cloud-native SaaS platform for analyzing, standardizing, and interpreting complex healthcare data (genomic, radiomic, multimodal). Includes modules for Genomics, Radiomics, and Multimodal analysis.
- SOPHiA DDM™ Digital Twins
- MSK-ACCESS® powered with SOPHiA DDM™
- Alamut™ Visual Plus
- MSK-IMPACT® Flex powered with SOPHiA DDM™
Products and services
- SOPHiA DDM™ Platform
- SOPHiA DDM™ for Genomics
Quantifiable outcome
- 22% year-over-year revenue growth in Q1 2026 ($21.7M) and 19% growth in full-year 2025 ($77.3M); 20-22% projected for 2026.
- +9 more outcomes
Companies that use SOPHiA GENETICS
Customer profileNamed customers18 records
Segments3 records
Ideal customer profiles2 records
SOPHiA GENETICS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration11 records
AI capability12 records
Feature13 records
SOPHiA GENETICS partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered flagship, core and minor.
- Memorial Sloan Kettering Cancer Center (MSK)flagshipSigned an MOU in June 2026 to form a joint venture establishing a precision medicine hub in New York City combining MSK's clinical data and 150,000+ sequenced tumor samples with SOPHiA DDM AI. Builds on previous licensing of MSK-IMPACT and MSK-ACCESS assays reaching 35 countries and a long-running co-development partnership on liquid biopsy (MSK-ACCESS) and comprehensive genomic profiling (MSK-IMPACT).
- SynnoviscoreUK pathology provider partnership to deliver MSK-ACCESS® liquid biopsy testing powered with SOPHiA DDM™ to lung and breast cancer patients across the U.K. as part of NHS England's 'blood test-first' program. Anticipates testing ~7,000 patients annually (≈one-third of all ctDNA tests in England), with patients receiving targeted therapy up to two weeks earlier.
- Mount Sinai Health SystemflagshipMount Sinai adopted the SOPHiA DDM™ Platform at its NCI-designated Comprehensive Cancer Center in New York to enhance genomic testing for blood cancers and solid tumors, supporting 4,000+ oncology patients annually. Connects Mount Sinai's molecular pathology teams to a network of 800+ global institutions.
- Element BiosciencescoreExpanded partnership to integrate SOPHiA's AI-powered analytics with Element's AVITI and AVITI24 sequencing platforms. Joint go-to-market for clinical oncology research and targeted sequencing workflows.
- Mayo Clinic (expanded U.S. footprint)corePart of the major U.S. expansion adding two large U.S. healthcare systems for genomic testing on up to 60,000 patients annually, leveraging the AI-native SOPHiA DDM platform.
- Two major U.S. integrated health systems (West Coast and Midwest)coreSigned two major integrated health systems (a leading nonprofit multi-region integrated healthcare system and a top 10 U.S. health system laboratory) to deploy the SOPHiA DDM Platform for hereditary cancers and rare diseases, with up to 60,000 patients tested annually.
- The University of Texas MD Anderson Cancer CenterflagshipStrategic collaboration to co-develop a next-generation sequencing oncology test on the SOPHiA DDM Platform and launch joint R&D programs focused on tumor evolution characterization, genomic testing reliability, and patient-specific clinical trial identification. Aims to translate multimodal data including RNA-sequencing into actionable insights for cancer diagnosis and treatment.
- Complete GenomicscoreIntegration of MSK-IMPACT and MSK-ACCESS assays on the Complete Genomics DNBSEQ-T1+ sequencing platform, announced at AMP 2025. Provides laboratories with an end-to-end sample-to-report workflow for both liquid biopsy and solid tumor testing with concordant variant calls and lower background noise.
- A.D.A.M. Innovations Corporation (Japan)coreStrategic partnership in Japan to develop and commercialize liquid biopsy testing for personalized cancer care, initially launching the MSK-ACCESS® application. Samples analyzed locally in Japan to expedite turnaround times, reduce patient costs, and develop companion diagnostic tests.
- Myriad GeneticsflagshipFirst-of-its-kind hybrid CDx partnership combining Myriad's centralized CDx and regulatory expertise with SOPHiA's decentralized, data-driven platform. Co-developing an innovative liquid biopsy companion diagnostic test (initially MSK-ACCESS) for global clinical trials and healthcare.
- Jessa ZiekenhuisminorAnnounced precision oncology partnership from the European Congress of Pathology to deploy SOPHiA DDM solutions for the hospital.
- AstraZenecaflagshipExpanded collaboration to use SOPHiA DDM AI to improve detection of breast and prostate cancer and to accelerate liquid biopsy testing globally. AstraZeneca's AI strategy uses multimodal data from this partnership to tailor treatments to cancer patients.
- Mayo CliniccoreNew partnership mentioned alongside SOPHiA's 2024 growth initiatives and Q1 2024 revenue results, supporting platform expansion and clinical use.
- ADC TherapeuticscoreCollaboration to identify genomic mutations correlating with clinical response to ADCT-402 in relapsed or refractory diffuse large B-cell lymphoma using SOPHiA's unique decentralized platform.
- Boundless BiocorePartnering to develop the ECHO ecDNA detection algorithm into a clinical trial device on SOPHiA's cloud-based IVD NGS software platform.
- ARC RegulatorycoreCollaboration to deliver an integrated solution for pharma companies in late-stage clinical development in Europe. Combines ARC Regulatory's IVDR-compliant clinical performance studies expertise with SOPHiA GENETICS' NGS technology and CE-IVD track record, starting with co-development of a Clinical Trial Assay.
- Precision for MedicinecoreStrategic alliance combining wet lab and translational expertise with SOPHiA's advanced analytics. Develops flexible clinical trial solutions that derive molecular signatures from complex data, advancing precision medicine through data-driven collaboration.
Scale indicators16 records
Recent moves8 records
Expansion highlights7 records
SOPHiA GENETICS competitors and assessment
Company assessmentEmerging players
- Natera: Cell-free DNA testing company (Signatera MRD, Empower, Vistara) with a clinical biopharma services unit. Comparable in MRD/cfDNA testing, technology stack, and BioPharma customer segment, though more focused on solid-tumor recurrence than SOPHiA's broader CDx play.
- NeoGenomics: Clinical oncology and hematology lab with both wet-lab CGP services and an informatics platform (NeoGenomics Analytics). Comparable in oncology genomics lab services, hospital sales motion, and growing biopharma/CDx business.
- Personalis: Smaller oncology genomics company focused on CGP (NeXT Personal) and immuno-oncology biomarker analytics. Comparable in technology and customer type but at a smaller scale and narrower indication focus than SOPHiA.
- Veracyte: Genomic diagnostics company (Afirma, Decipher, Prosigna) with a growing AI/biomarker platform and BioPharma services arm. Comparable in the genomic test + biopharma CDx/data analytics model, though historically stronger in urologic/thyroid indications than oncology broadly.
Direct peers
- Tempus AI: Publicly traded AI-driven precision medicine company offering multimodal data analytics (genomics, imaging, clinical) for oncology providers and BioPharma. Closely comparable to SOPHiA GENETICS in business model, technology stack, customer base, and go-to-market motion.
- Caris Life Sciences: AI-driven molecular profiling company (MI Profile, Caris Assure) with both a sequencing services business and an AI/biopharma platform (Caris Discovery). Comparable because it serves the same oncology providers and biopharma customers with molecular profiling plus data analytics.
- Guardant Health: Liquid biopsy and oncology genomics company with its own proprietary cfDNA assays (Guardant360, Shield) and AI/ML pipelines. Directly comparable in oncology liquid biopsy, the specific area where SOPHiA is building MSK-ACCESS-powered CDx, and is also a litigation counterparty.
Others
- DNAnexus: Cloud-based genomics data management and analysis platform serving pharma, clinical labs, and research consortia. Comparable as a backend cloud genomics platform, though more of a horizontal infrastructure provider than a clinical-decision-support vendor.
Broad incumbents
- Illumina: Dominant NGS sequencing platform vendor that also offers DRAGEN bioinformatics software and IVD kits. Comparable because it competes for the same hospital sequencing + analysis budget and bundles its own software stack against SOPHiA DDM.
- Foundation Medicine (Roche): Roche subsidiary offering FoundationOne CDx comprehensive genomic profiling and a data analytics platform for oncology. Comparable in CGP, biopharma CDx services, and in competing for the same academic cancer center and pharma customers as SOPHiA.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
SOPHiA GENETICS social profiles
Digital presenceSOPHiA GENETICS compliance and trust
Trust signalCompliance9 records
SOPHiA GENETICS financial estimates
Financial estimateRevenue estimate
Valuation estimate
SOPHiA GENETICS leadership team
Management profileNumber of profiles
Profiles13 records
SOPHiA GENETICS subsidiaries and ownership
Company hierarchySubsidiaries1 record
SOPHiA GENETICS funding detail
Funding detailFunding overview
Funding rounds9 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SOPHiA GENETICS M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SOPHiA GENETICS
What does SOPHiA GENETICS do?
SOPHiA GENETICS builds and operates the SOPHiA DDM™ cloud-native AI platform that ingests raw NGS, radiomic and multimodal data and produces standardized, clinically validated variant interpretations and reports for hospitals, clinical laboratories and biopharma customers across 75+ countries. The platform is delivered as enterprise SaaS (Dry Lab, Bundle, Integrated Access Mode), with proprietary molecular barcoding (CUMIN®) and a suite of calling algorithms enabling CE-IVD genomic applications in oncology and rare disorders, and supports companion diagnostic co-development with pharmaceutical partners.
Is SOPHiA GENETICS a public or private company?
SOPHiA GENETICS is a public company. It is classified as public and is currently operating.
When was SOPHiA GENETICS founded?
SOPHiA GENETICS was founded in 2011. It employs 501 to 1,000 people.
Where is SOPHiA GENETICS based?
SOPHiA GENETICS is headquartered in Boston, United States, in the North America region.
How does SOPHiA GENETICS make money?
Five revenue lines are on record. Platform Subscription / Recurring SaaS are the primary driver. The others are usage-Based Analysis Volume, bioPharma Companion Diagnostic & Trial Services, alamut™ Visual Plus Licensing and professional Services & MaxCare Program.
Who are SOPHiA GENETICS's main competitors?
Emerging players on record are Natera, NeoGenomics, Personalis and Veracyte. Direct peers are Tempus AI, Caris Life Sciences and Guardant Health. DNAnexus is listed as an others. Broad incumbents are Illumina and Foundation Medicine (Roche).
Does SOPHiA GENETICS have an API?
No public API is recorded for SOPHiA GENETICS.
What industry is SOPHiA GENETICS in?
SOPHiA GENETICS's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D), with a secondary code of HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services. Its NAICS code is 541714 and its SIC code is 8071.